Oxaliplatin
Chemical Name: Oxalato[(1R-trans)-1,2-cyclohexanediamine]platinum(II)
Purity: ≥99%
Biological Activity
Oxaliplatin is an antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (Cat. No. 2251) and shows antitumor activity in cell lines with acquired cisplatin resistance.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy et al.
Drugs, 2000;60:895 -
Oxaliplatin: a review of evolving concepts.
Mani et al.
Cancer Invest., 2002;20:246 -
Cellular and molecular pharmacology of oxalip.
Raymond et al.
Mol.Cancer Ther., 2002;1:227
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for Oxaliplatin
The citations listed below are publications that use Tocris products. Selected citations for Oxaliplatin include:
7 Citations: Showing 1 - 7
-
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Authors: Li Et al.
BMC Cancer 2015;6:9240
-
Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC.
Authors: Massey
PLoS One 2015;10:e0134306
-
Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line.
Authors: Fukushima Et al.
Cancer Sci 2015;106:1000
-
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Authors: Bryant Et al.
Exp Neurol 2014;14:570
-
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
Authors: Rawlinson
BMC Cancer 2014;14:483
-
A high throughput scintillation proximity imaging assay for protein methyltransferases.
Authors: Ibáñez Et al.
Comb Chem High Throughput Screen 2012;15:359
-
Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by MinCyc.
Authors: Boyette-Davis and Dougherty
Oncotarget 2011;229:353
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for Oxaliplatin
There are currently no reviews for this product. Be the first to review Oxaliplatin and earn rewards!
Have you used Oxaliplatin?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
